Article info

Original research
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

Authors

  1. Correspondence to Dr Stephanie Licata; stephanie.licata{at}biogen.com
View Full Text

Citation

Butzkueven H, Licata S, Jeffery D on behalf of the REVEAL Investigators, et al
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

Publication history

  • Received March 26, 2020
  • Revised September 2, 2020
  • Accepted September 3, 2020
  • First published October 20, 2020.
Online issue publication 
October 20, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.